We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+57.75%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.48B
AUM Growth
+$1.48B
Cap. Flow
+$437M
Cap. Flow %
9.75%
Top 10 Hldgs %
48.38%
Holding
120
New
23
Increased
28
Reduced
22
Closed
19

Top Buys

Rank Stock Value
1
CRGX
CARGO Therapeutics
CRGX
+$58.3M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$55.9M
3
AXSM icon
Axsome Therapeutics
AXSM
+$37.2M
4
SYRE icon
Spyre Therapeutics
SYRE
+$34.8M
5
ABBV icon
AbbVie
ABBV
+$34.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$74M
2
IMVT icon
Immunovant
IMVT
+$54.7M
3
ROIV icon
Roivant Sciences
ROIV
+$44.6M
4
HRMY icon
Harmony Biosciences
HRMY
+$32.6M
5
RLAY icon
Relay Therapeutics
RLAY
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRCA icon
26
Verrica Pharmaceuticals
VRCA
$96M
$52M 1.16%
709,918
+206,020
+41% +$8.47M
RCKT icon
27
Rocket Pharmaceuticals
RCKT
$342M
$51.2M 1.14%
1,707,398
+189,931
+13% +$4.19M
APGE icon
28
Apogee Therapeutics
APGE
$10.2B
$51.1M 1.14%
1,827,901
– –
XENE icon
29
Xenon Pharmaceuticals
XENE
$6.19B
$50.7M 1.13%
1,100,748
+483,248
+78% +$17.1M
RYZB
30
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$46.3M 1.03%
744,056
-32,749
-4% -$814K
CABA icon
31
Cabaletta Bio
CABA
$439M
$45.5M 1.01%
2,003,058
+870,567
+77% +$14.6M
CRNX icon
32
Crinetics Pharmaceuticals
CRNX
$8.88B
$44.7M 1%
1,255,512
-8,220
-0.7% -$252K
SRPT icon
33
Sarepta Therapeutics
SRPT
$1.66B
$43.6M 0.97%
451,873
+269,153
+147% +$25.8M
EOLS icon
34
Evolus
EOLS
$403M
$41.7M 0.93%
3,963,424
+2,477,623
+167% +$22.2M
VRDN icon
35
Viridian Therapeutics
VRDN
$2.17B
$37.7M 0.84%
1,730,212
+719,007
+71% +$11.4M
NAUT icon
36
Nautilus Biotechnolgy
NAUT
$139M
$37.7M 0.84%
12,594,211
+3,483,060
+38% +$9.97M
ABBV icon
37
AbbVie
ABBV
$471B
$36.9M 0.82%
+238,000
New +$34.7M
IMTX icon
38
Immatics
IMTX
$1.22B
$36.8M 0.82%
3,491,500
– –
NBIX icon
39
Neurocrine Biosciences
NBIX
$18.3B
$35.7M 0.8%
270,794
+111,552
+70% +$12.8M
MDGL icon
40
Madrigal Pharmaceuticals
MDGL
$12.6B
$35M 0.78%
151,151
+26,514
+21% +$4.64M
ATXS
41
DELISTED
Astria Therapeutics
ATXS
$30.8M 0.69%
4,004,070
+1,814,608
+83% +$10M
ALDX icon
42
Aldeyra Therapeutics
ALDX
$95.9M
$30.2M 0.67%
8,593,586
-2,756,499
-24% -$8.51M
ADMA icon
43
ADMA Biologics
ADMA
$2.06B
$29.1M 0.65%
6,433,369
-550,950
-8% -$2.04M
AMLX icon
44
Amylyx Pharmaceuticals
AMLX
$2.21B
$27.5M 0.61%
1,869,125
-819,748
-30% -$12.6M
FUSN
45
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$26.4M 0.59%
2,751,395
– –
TARS icon
46
Tarsus Pharmaceuticals
TARS
$2.53B
$26.3M 0.59%
1,296,416
– –
RVMD icon
47
Revolution Medicines
RVMD
$38.9B
$23.5M 0.52%
818,882
-502,913
-38% -$12.1M
AKRO
48
DELISTED
Akero Therapeutics
AKRO
$22.6M 0.5%
967,775
-651,650
-40% -$12.9M
OBIO icon
49
Orchestra BioMed
OBIO
$234M
$22.2M 0.5%
2,432,089
– –
CELC icon
50
Celcuity
CELC
$4.08B
$21.6M 0.48%
+1,481,300
New +$17.9M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Perceptive Advisors held 120 positions worth $4.48B, up 49% from $3B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $437M of net new capital in Q4 2023, opening 23 new positions and adding to 28 existing holdings. Its largest new stake was CARGO Therapeutics: 3,436,600 shares worth $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Immunovant, an estimated $54.7M trimmed.

  • Perceptive Advisors's largest Q4 2023 buy was CARGO Therapeutics: 3,436,600 shares worth $79.6M.
  • Perceptive Advisors added most to Rhythm Pharmaceuticals in Q4 2023, an estimated $55.9M increase.
  • Perceptive Advisors's biggest Q4 2023 reduction was Immunovant, cutting an estimated $54.7M.
  • Perceptive Advisors fully exited argenx in Q4 2023, selling an estimated $74M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $4.48B portfolio in Q4 2023.
  • Perceptive Advisors opened 23 new positions and closed 19 in Q4 2023.
  • Perceptive Advisors's portfolio value rose 49% quarter-over-quarter to $4.48B.

Based on Perceptive Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.